In the realm of contemporary oncology, the development and use of novel therapeutic agents, including immune checkpoint inhibitors (ICIs) and anti-vascular endothelial growth factor (VEGF) therapies, mark a paradigm shift in cancer treatment. These advanced therapeutics, while undoubtedly enhancing survival outcomes, have ushered in a new spectrum of renal complications, opening an unexplored frontier of nephrotoxicity that necessitates detailed investigation.
The imperative to understand the renal consequences of these therapies stems from the crucial role the kidneys play in drug clearance, and their susceptibility to drug-induced injury. Nephrotoxic effects can significantly alter treatment course, compromise therapeutic effectiveness, and may precipitate acute kidney injury (AKI) or contribute to chronic kidney disease (CKD) progression. Such renal adversities can markedly impact patient morbidity, mortality, and overall quality of life.
This collection aims to bring together cutting-edge research and comprehensive reviews elucidating the nephrotoxicity associated with ICIs, anti-VEGF agents, and other innovative anti-neoplastic modalities. We invite contributions investigating underlying mechanisms of renal injury, clinical manifestations, and management strategies of drug-induced nephrotoxicity. Furthermore, we encourage submissions focused on biomarkers predictive of renal injury, strategies for early detection, and the correlation between renal function and cancer prognosis under these therapies.
Keywords: Nephrotoxicity, Immune Checkpoint Inhibitors, Anti-VEGF Therapies, Drug-Induced Kidney Injury, Chemotherapy
Dr. Andrea Angioi, M.D. is a highly experienced nephrologist currently serving as a Consultant at the Division of Nephrology and Dialysis at the Azienda Ospedaliera G. Brotzu in Cagliari, Italy. He completed his medical studies with distinction at the University of Cagliari and received his fellowship in Nephrology from the University of Sassari. Dr. Angioi's career includes a significant period of research at the Mayo Clinic College of Medicine, Rochester, MN, where he contributed to the field of nephrology and hypertension. He is a Fellow of the American Society of Nephrology and maintains active memberships with several professional societies including the Renal Pathology Society and the Italian Society of Nephrology. Dr. Angioi's clinical and research interests include renal transplantation, immune-mediated nephropathies, renal pathology, and ultrasound imaging in nephrology. For more details, please visit the institutional page of the Azienda Ospedaliera G. Brotzu (www.aobrotzu.it).
A. Emre Eşkazan, M.D. is a Professor of Internal Medicine and Hematology currently working in the Division of Hematology, Department of Internal Medicine at the Cerrahpaşa Faculty of Medicine of the Istanbul University-Cerrahpaşa, Istanbul. He is the head of Chronic Myeloid Leukemia (CML), and Myeloproliferative Neoplasm (MPN) Scientific Subcommittee of the Turkish Society of Hematology and a member of the European Society of Hematology Scientific Working Group on CML. Dr. Eşkazan has authored more than 150 peer-reviewed publications. His main research topics are myeloid malignancies including, CML, MPNs, and AML.
Disclosure Statement: Dr. Andrea Angioi and Dr. A. Emre Eşkazan declare there is no conflict of interest.
